V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240008722 | 240005327 | 1.63 | 84 | Not known (9) | 2016-01-21 | 2016-01-22 | BEVACIZUMAB + CISPLATIN + PACLITAXEL | 2 | N | 240021285 | CHOEP |
| 240008723 | 240005327 | null | 83.1 | Disease modification (D) | 2013-11-05 | 2013-11-10 | R CODOX M | N | N | 240021285 | CISPLATIN + ETOPOSIDE |
| 240008724 | 240005327 | 1.72 | 73 | Palliative (P) | 2014-03-02 | 2014-03-06 | DA-EPOCH-R | 2 | N | 240021285 | R-EPOCH |
| 240008725 | 240014977 | null | 69.9 | Curative (C) | 2016-09-09 | 2016-09-14 | AML17 TRIAL | 2 | N | 240021487 | OXALIPLATIN + MDG |
| 240008726 | 240014977 | 1.65 | 88.4 | Palliative (P) | 2015-06-04 | 2015-06-05 | Cisplatin + Doxorubicin | null | N | 240021487 | BLEOMYCIN + CISPLATIN + MTOMYCIN |
| 240008727 | 240005328 | 1.85 | 84 | Adjuvant (A) | 2014-06-12 | 2014-06-12 | Capecitabine (14 day) + Irinotecan | 2 | N | 240021606 | WT1 TRIAL |
| 240008728 | 240005329 | 1.71 | 56.8 | Curative (C) | 2015-12-13 | 2015-12-17 | GemCarbo Days 1+8 | 1 | N | 240021702 | BEVACIZUMAB + CISPLATIN + PACLITAXEL |
| 240008729 | 240005330 | 1.76 | 63 | Curative (C) | 2016-09-24 | 2016-10-07 | DHAP - R | Y | N | 240021713 | CODOX M |
| 240008730 | 240005331 | 1.68 | 66 | Curative (C) | 2017-02-11 | 2017-04-20 | FCR Oral - Cycle 2 onwards | N | Y | 240021717 | BCG |
| 240008731 | 240005332 | 1.67 | 80 | null | 2017-03-12 | 2017-04-01 | FLAG | 99 | N | 240021767 | CODOX M |
| 240008732 | 240005332 | 1.56 | 62 | Adjuvant (A) | 2016-01-30 | 2016-01-30 | Gemcitabine 1000mg/m2 D1 8 15 | 2 | N | 240021767 | CISPLATIN + TOPOTECAN |
| 240008733 | 240005333 | 1.56 | 66 | Palliative (P) | 2016-05-02 | 2016-05-04 | FLUOROURACIL + MITOMYCIN | 02 | N | 240021787 | CVP |
| 240008734 | 240005334 | 1.74 | 88.8 | Neo-adjuvant (N) | 2013-11-15 | 2013-11-16 | CHOEP - 21 days | 1 | N | 240021795 | CLADRIBINE |
| 240008735 | 240005334 | 1.7 | 80.8 | Palliative (P) | 2016-10-13 | 2016-10-13 | REMODLB TRIAL | 02 | N | 240021795 | CISPLATIN + TOPOTECAN |
| 240008736 | 240005335 | 1.64 | 80 | Curative (C) | 2017-01-27 | 2017-01-27 | BEP 5 Day | N | N | 240021881 | CISPLATIN + ETOPOSIDE |
| 240008737 | 240005336 | 1.66 | null | Not known (9) | 2014-04-12 | 2014-04-12 | Triple / Double Intrathecal Therapy | 02 | N | 240021950 | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE |
| 240008738 | 240005337 | 1.49 | 55.2 | Palliative (P) | 2013-03-04 | 2013-03-06 | Doxorubicin + Olaratumab | 02 | N | 240021958 | CARBOPLATIN + RT |
| 240008739 | 240005337 | 1.76 | 103.7 | Curative (C) | 2017-08-14 | 2017-08-16 | AML17 TRIAL | 02 | N | 240021958 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 240008740 | 240005337 | 1.61 | 37 | Disease modification (D) | 2016-06-17 | 2016-06-21 | CISPLATIN + FLUOROURACIL + RT | N | N | 240021958 | CYCLO + RITUXIMAB + VINCRISTINE |
| 240008742 | 240005339 | null | 55.4 | null | 2014-03-05 | 2014-03-07 | Cisplatin + Topotecan | N | N | 240022028 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008743 | 240005340 | 1.6 | 63.2 | Palliative (P) | 2015-07-03 | 2015-07-03 | FCR Oral - Cycle 2 onwards | 02 | N | 240022032 | BENDAMUSTINE + BORTEZOMIB |
| 240008744 | 240005341 | 1.56 | 108.8 | Palliative (P) | 2018-07-12 | 2018-07-12 | ABVD | 02 | null | 240022100 | CISPLATIN + PACLITAXEL |
| 240008745 | 240005342 | 1.75 | null | Curative (C) | null | 2017-07-24 | CHLORAMBUCIL + OBINUTUZUMAB | N | null | 240022117 | CYCLOPHOSPHAMIDE |
| 240008746 | 240005342 | 1.68 | 82 | Palliative (P) | 2015-10-04 | 2015-10-08 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | 01 | N | 240022117 | CISPLATIN + ETOPOSIDE |
| 240008747 | 240013645 | 1.49 | 95 | Disease modification (D) | 2016-02-21 | 2016-02-22 | CISPLATIN + FLUOROURACIL + RT | N | N | 240022133 | EP |
| 240008748 | 240005343 | null | 89.2 | Palliative (P) | 2014-10-19 | 2014-10-21 | BCG Intravesical | null | N | 240022152 | CVP |
| 240008749 | 240005344 | null | 85.95 | Not known (9) | 2018-07-03 | 2018-07-03 | BEVACIZUMAB + CISPLATIN + PACLITAXEL | null | N | 240022183 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 240008750 | 240005344 | 1.58 | 84 | Disease modification (D) | 2017-11-13 | 2017-11-13 | CISPLATIN + VINORELBINE | 02 | N | 240022183 | FCR |
| 240008751 | 240005344 | 1.7 | 43.6 | Disease modification (D) | 2018-01-03 | 2018-01-16 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 02 | N | 240022183 | CISPLATIN + FLUOROURACIL |
| 240008752 | 240005345 | 1.53 | 113.9 | Curative (C) | null | 2018-08-30 | CODOX M | N | N | 240022267 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008753 | 240005346 | 1.6 | 51 | Curative (C) | 2014-05-11 | 2014-05-11 | Cyclophosphamide + Dex + Rituximab | Y | N | 240022285 | DHAP - R |
| 240008754 | 240005347 | 1.71 | 60.9 | Palliative (P) | 2018-01-09 | 2018-03-09 | Gemcitabine + Oxaliplatin | N | N | 240022291 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 240008755 | 240010938 | 1.67 | 61.5 | Disease modification (D) | 2016-11-02 | 2016-11-02 | Lomustine | 1 | N | 240022298 | CAPECITABINE |
| 240008756 | 240005348 | 1.68 | 49 | Palliative (P) | 2017-10-16 | 2017-11-06 | DA-EPOCH-R | N | N | 240022301 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008757 | 240005349 | null | 73 | Adjuvant (A) | 2016-09-05 | 2016-09-07 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | N | 240022334 | CTD |
| 240008758 | 240005349 | 1.63 | 73.1 | Palliative (P) | 2014-10-18 | 2014-10-18 | Cisplatin + Etoposide (3 day) | 02 | N | 240022334 | BEVACIZUMAB + CARBO |
| 240008759 | 240005350 | 1.7 | 104 | Curative (C) | 2017-10-06 | 2017-10-06 | CISPLATIN + ETOPOSIDE | 02 | N | 240022392 | CARBOPLATIN + IFOSFAMIDE |
| 240008760 | 240005351 | 1.53 | 63.9 | Curative (C) | 2014-04-19 | 2014-04-29 | CYCLO + RITUXIMAB + VINCRISTINE | 02 | N | 240022426 | CISPLATIN + VINORELBINE |
| 240008761 | 240010940 | 1.58 | 47 | Curative (C) | 2018-09-14 | 2018-09-14 | Bevacizumab 15mg/kg | N | N | 240022434 | MITOXANTRONE |
| 240008762 | 240005352 | 1.53 | 64.4 | Palliative (P) | 2014-09-21 | 2014-10-15 | CISPLATIN + FLUOROURACIL + RT | N | null | 240022447 | FCR |
| 240008763 | 240005352 | 1.72 | 62.2 | Curative (C) | 2013-07-20 | 2013-07-23 | AML16 DA 3+10 | N | N | 240022447 | CYTARABINE HIGH DOSE |
| 240008764 | 240005353 | 1.6 | null | Curative (C) | 2013-02-22 | 2013-02-22 | GEMCARBO | 02 | N | 240022512 | GEMCARBO |
| 240008765 | 240005354 | 1.52 | 54.1 | Curative (C) | null | 2017-08-20 | Cisplatin + Etoposide (3 day) | null | null | 240022526 | CAPECITABINE + OXALIPLATIN |
| 240008766 | 240010942 | 1.7 | 71 | Palliative (P) | 2013-08-07 | 2013-08-10 | ABVD | N | N | 240022571 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008767 | 240005355 | null | 40.2 | null | 2017-03-16 | 2017-04-07 | CARBOPLATIN + PACLITAXEL + RT | N | null | 240022592 | CISPLATIN + VINORELBINE |
| 240008768 | 240010943 | 1.52 | 62 | Palliative (P) | 2013-08-01 | 2013-08-06 | Bortezomib + CYCLOPHOSPHAMIDE | N | N | 240022593 | SUNITINIB |
| 240008769 | 240010943 | 1.8 | 54.6 | Adjuvant (A) | 2014-10-12 | 2014-10-12 | MPV (cycle 1-4) | 02 | N | 240022593 | IPILIMUMAB |
| 240008770 | 240005356 | 1.52 | 71 | Neo-adjuvant (N) | 2015-07-14 | 2015-07-14 | Carboplatin + Pemetrexed | N | N | 240022621 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008771 | 240005357 | 1.73 | 76.8 | Unknown (U) | 2017-05-08 | 2017-05-09 | CODOX M | N | N | 240022623 | TRASTUZUMAB |
| 240008772 | 240005358 | 1.61 | null | Palliative (P) | 2018-03-08 | 2018-03-20 | Cytarabine Low Dose | 02 | N | 240022635 | GEMCARBO |